» Articles » PMID: 20691958

G Protein-coupled Receptor Heteromers As New Targets for Drug Development

Overview
Specialty Molecular Biology
Date 2010 Aug 10
PMID 20691958
Citations 25
Authors
Affiliations
Soon will be listed here.
Abstract

We now have a significant amount of experimental evidence that indicates that G protein-coupled receptor (GPCR) oligomerization, including homo- and heteromerization, is a general phenomenon. Receptor heteromers possess unique biochemical characteristics that are demonstrably different from those of its individual units. These properties include allosteric modulation(s) between units, changes in ligand recognition, G protein-coupling and trafficking. The discovery of GPCR oligomers have been related to the parallel discovery and application of a variety of resonance energy transfer (RET) techniques, such as bioluminescence, fluorescence and sequential RET (BRET, FRET and SRET, respectively), time-resolved FRET (T-FRET) and fluorescence recovery after photobleaching (FRAP) microscopy. However, RET techniques are difficult to implement in native tissues. For receptor heteromers, indirect approaches, such as the determination of a unique biochemical characteristic ("biochemical fingerprint"), permit their identification in native tissues and their use as targets for drug development. Dopamine and opioid receptor heteromers are the focus of intense research which is related to the possible multiple applications of their putative ligands in pathological conditions, which include basal ganglia disorders, schizophrenia and drug addiction.

Citing Articles

Pharmacological targeting of G protein-coupled receptor heteromers.

Moreno E, Casajuana-Martin N, Coyle M, Campos B, Galaj E, Llinas Del Torrent C Pharmacol Res. 2022; 185:106476.

PMID: 36182040 PMC: 9645299. DOI: 10.1016/j.phrs.2022.106476.


Endocannabinoid-Binding Receptors as Drug Targets.

Gomez-Canas M, Rodriguez-Cueto C, Satta V, Hernandez-Fisac I, Navarro E, Fernandez-Ruiz J Methods Mol Biol. 2022; 2576:67-94.

PMID: 36152178 DOI: 10.1007/978-1-0716-2728-0_6.


Pathophysiological Role and Medicinal Chemistry of A Adenosine Receptor Antagonists in Alzheimer's Disease.

Merighi S, Borea P, Varani K, Vincenzi F, Travagli A, Nigro M Molecules. 2022; 27(9).

PMID: 35566035 PMC: 9102440. DOI: 10.3390/molecules27092680.


A Adenosine Receptor Antagonists in Neurodegenerative Diseases.

Merighi S, Borea P, Varani K, Vincenzi F, Jacobson K, Gessi S Curr Med Chem. 2021; 29(24):4138-4151.

PMID: 34844537 PMC: 9148371. DOI: 10.2174/0929867328666211129122550.


A Adenosine Receptor as a Potential Biomarker and a Possible Therapeutic Target in Alzheimer's Disease.

Gessi S, Poloni T, Negro G, Varani K, Pasquini S, Vincenzi F Cells. 2021; 10(9).

PMID: 34571993 PMC: 8469578. DOI: 10.3390/cells10092344.


References
1.
Rashid A, So C, Kong M, Furtak T, El-Ghundi M, Cheng R . D1-D2 dopamine receptor heterooligomers with unique pharmacology are coupled to rapid activation of Gq/11 in the striatum. Proc Natl Acad Sci U S A. 2006; 104(2):654-9. PMC: 1766439. DOI: 10.1073/pnas.0604049104. View

2.
Marcellino D, Ferre S, Casado V, Cortes A, Le Foll B, Mazzola C . Identification of dopamine D1-D3 receptor heteromers. Indications for a role of synergistic D1-D3 receptor interactions in the striatum. J Biol Chem. 2008; 283(38):26016-25. PMC: 2533781. DOI: 10.1074/jbc.M710349200. View

3.
Pin J, Neubig R, Bouvier M, Devi L, Filizola M, Javitch J . International Union of Basic and Clinical Pharmacology. LXVII. Recommendations for the recognition and nomenclature of G protein-coupled receptor heteromultimers. Pharmacol Rev. 2007; 59(1):5-13. DOI: 10.1124/pr.59.1.5. View

4.
Simpson L, Taddese B, Wall I, Reynolds C . Bioinformatics and molecular modelling approaches to GPCR oligomerization. Curr Opin Pharmacol. 2009; 10(1):30-7. DOI: 10.1016/j.coph.2009.11.001. View

5.
Milligan G, Smith N . Allosteric modulation of heterodimeric G-protein-coupled receptors. Trends Pharmacol Sci. 2007; 28(12):615-20. DOI: 10.1016/j.tips.2007.11.001. View